Continuous Glucose Monitoring Devices Market Size & Growth Forecast 2027–2036, By Segments (Product, Indication, Distribution Channel, Connectivity, Region), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Continuous Glucose Monitoring Devices Market size was estimated at USD 15.5 billion in 2026 and is projected to grow at a 14.35% CAGR from 2027 to 2036, exceeding USD 59.25 billion by 2036. The industry revenue for 2027 is calculated at USD 17.37 billion.

• Base Year Value (2026): USD 15.5 billion
• CAGR (2027-2036): 14.35%
• Forecast Year Value (2036): USD 59.25 billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Continuous Glucose Monitoring Devices Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America held a 59.64% share in 2026, supported by strong reimbursement, high patient awareness, and broad integration of sensor-based glucose monitoring into routine diabetes care.
  • Asia Pacific is projected to grow at an 8.14% CAGR due to rising diabetes prevalence, improving healthcare access, and increasing adoption of continuous monitoring technologies.

• Segment Momentum:

  • Standalone CGM Devices held a 75.17% share in 2026 because they can be adopted without connected insulin delivery platforms, offering flexible deployment and compatibility with routine diabetes management practices.
  • Type 2 Diabetes is the fastest-growing indication as continuous glucose monitoring expands beyond intensive insulin users, supporting broader disease management and increasing adoption across a larger patient population.

• Market Expansion Drivers:

  • Rising diabetes prevalence driving demand for real-time continuous glucose monitoring systems globally.
  • Integration of Bluetooth-enabled wearable sensors improving patient connectivity and remote monitoring.
  • Expanding reimbursement coverage and remote patient monitoring programs accelerating CGM adoption rates.

• Leading Market Participants:

  Leading players in the continuous glucose monitoring devices market include DexCom, Inc. (United States), Abbott Laboratories (United States), Medtronic plc (Ireland), F. Hoffmann-La Roche AG (Switzerland), Senseonics Holdings, Inc. (United States), Sinocare Inc. (China), i-SENS, Inc. (South Korea), Zhejiang POCTech Co., Ltd. (China), Nemaura Medical Inc. (United Kingdom), Bionime Corporation (Taiwan).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 15.5 billion
  • 2027 Estimated Market Size: USD 17.37 billion.
  • Projected Market Size: USD 59.25 billion by 2036
  • Growth Forecasts: 14.35% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Standalone CGM Devices (Product) | Type 1 Diabetes (Indication) | Pharmacies (Distribution Channel) | Bluetooth (Connectivity) | North America (Region)
  • Emerging Opportunity Segment: Integrated-CGM Insulin Pump Systems (Product) | Type 2 Diabetes (Indication) | E-commerce (Distribution Channel) | Near Field Communication (NFC) (Connectivity) | Asia Pacific (Region)

Market Growth Drivers and Industry Trends

Rising diabetes prevalence driving demand for real-time continuous glucose monitoring systems globally

The continuous glucose monitoring devices market is gaining momentum as the growing prevalence of diabetes increases the need for continuous, convenient, and timely glucose assessment. A larger diabetic population requires more frequent monitoring to support treatment decisions, identify glucose fluctuations, and maintain better control of blood sugar levels. Unlike conventional testing approaches that provide readings at individual points in time, continuous monitoring systems can provide ongoing glucose information, helping patients and healthcare professionals better understand daily glucose patterns. The increasing emphasis on proactive diabetes management and personalized care is also encouraging wider consideration of real-time monitoring technologies across different patient groups.

Integration of Bluetooth-enabled wearable sensors improving patient connectivity and remote monitoring

Bluetooth-enabled connectivity is strengthening the continuous glucose monitoring devices market by making wearable glucose sensors more capable of transmitting readings to smartphones and other compatible digital devices. This connectivity allows patients to access glucose information more conveniently while enabling caregivers and healthcare professionals to monitor relevant data remotely when appropriate. Integration with mobile applications can further support alerts, data visualization, and the organization of glucose trends, reducing the dependence on manual recording. As healthcare delivery increasingly incorporates connected devices and digital monitoring, bluetooth functionality is improving the usability and accessibility of wearable glucose monitoring systems.

Expanding reimbursement coverage and remote patient monitoring programs accelerating CGM adoption rates

Broader reimbursement coverage and the expansion of remote patient monitoring programs are reducing financial and access-related barriers associated with continuous glucose monitoring technologies. The continuous glucose monitoring devices market benefits as healthcare systems increasingly recognize the value of connected monitoring in supporting ongoing diabetes management outside conventional clinical settings. Reimbursement can make these devices more accessible to eligible patients, while remote monitoring programs create additional opportunities for healthcare providers to incorporate glucose data into routine follow-up and treatment management. Greater integration of monitoring technologies into digitally enabled care models can also encourage sustained use among patients who require regular oversight of glucose levels.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising diabetes prevalence driving demand for real-time continuous glucose monitoring systems globally	2.00%	High	North America, Asia Pacific	High	Near Term
Integration of Bluetooth-enabled wearable sensors improving patient connectivity and remote monitoring	1.80%	Moderate	North America, Europe	High	Mid Term
Expanding reimbursement coverage and remote patient monitoring programs accelerating CGM adoption rates	1.60%	High	North America, Europe	High	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the largest share of the continuous glucose monitoring devices market at 59.64% in 2026, supported by strong healthcare infrastructure, high awareness of diabetes management, and broad adoption of advanced glucose monitoring technologies. Greater emphasis on continuous disease management and personalized care is encouraging the use of real-time monitoring solutions among patients and healthcare providers. Established reimbursement frameworks, technological innovation, and increasing integration of connected health tools into diabetes care are further reinforcing regional demand.

Asia Pacific is anticipated to be the fastest-growing region, driven by expanding healthcare access, increasing awareness of diabetes management, and improving availability of advanced monitoring devices. Rising investment in healthcare infrastructure and the growing adoption of digital health technologies are making continuous monitoring solutions more accessible across the region. Increasing demand for convenient, patient-centered approaches to chronic disease management is also supporting broader adoption and creating favorable conditions for regional market expansion.

Key Country Insights

United States

Connected Diabetes Management

The U.S. continuous glucose monitoring devices market is driven by the integration of sensors with digital health platforms and insulin delivery systems. Broader reimbursement support and rising adoption among people with Type 2 diabetes are expanding the use of real-time glucose monitoring.

Japan

Precision Chronic Care Monitoring

Japan is incorporating continuous glucose monitoring devices into long-term diabetes management strategies, particularly for aging patient populations. Demand is increasing for compact, accurate sensors that support individualized treatment and remote healthcare services.

South Korea

Digital Health Integration Focus

South Korea is combining continuous glucose monitoring technologies with digital healthcare ecosystems and mobile applications. The market is characterized by growing interest in remote patient monitoring and connected diabetes management solutions that enhance treatment adherence.

Germany

Reimbursement-Led Adoption

Germany is strengthening the uptake of continuous glucose monitoring devices through established reimbursement pathways and increasing use in routine diabetes management. Healthcare providers are emphasizing data-driven monitoring approaches that improve treatment decisions and patient engagement.

France

Preventive Diabetes Management

France is expanding the use of continuous glucose monitoring devices to improve disease management and reduce complications associated with diabetes. Healthcare providers are increasingly utilizing sensor-based data to support personalized care and patient self-management practices.

Italy

Expanding Outpatient Monitoring

Italy is experiencing broader adoption of continuous glucose monitoring devices within outpatient diabetes care and specialist clinics. Greater awareness of the benefits of real-time glucose tracking is encouraging healthcare systems to integrate advanced monitoring technologies into routine care pathways.

Segment Leadership and Growth Trends

 

Product Segment Analysis: Standalone CGM Devices (Largest Segment) vs Integrated-CGM Insulin Pump Systems (Fastest-Growing Segment)

Standalone CGM devices dominated the continuous glucose monitoring devices market with a 75.17% share in 2026, reflecting their established role in providing continuous glucose information without requiring integration with an insulin delivery system. These devices offer users a convenient way to monitor glucose trends and support more informed diabetes management decisions. Their broad applicability across patients seeking continuous monitoring, combined with increasing awareness of glucose management and the benefits of real-time data, continues to sustain demand for standalone systems.

Integrated-CGM insulin pump systems are advancing rapidly as diabetes management increasingly moves toward connected and automated treatment approaches. Combining glucose sensing with insulin delivery can reduce the need to manage these functions separately and enable more coordinated therapy. Growing interest in automated insulin management, connected medical technologies, and simplified treatment workflows is strengthening the appeal of integrated systems among patients and healthcare providers.

Indication Segment Analysis: Type 1 Diabetes (Largest Segment) vs Type 2 Diabetes (Fastest-Growing Segment)

The type 1 diabetes segment represented the largest share of the continuous glucose monitoring devices market at 75.17% in 2026, owing to the intensive glucose monitoring requirements associated with insulin-dependent disease management. Continuous monitoring provides patients and clinicians with ongoing visibility into glucose fluctuations, helping support timely treatment adjustments and improved day-to-day management. Greater adoption of technology-enabled diabetes care and the clinical value of continuous glucose information continue to reinforce the segment's established position.

Type 2 diabetes is experiencing the fastest growth as continuous glucose monitoring becomes increasingly relevant beyond traditionally intensive insulin-management settings. Greater awareness of glucose patterns and the importance of personalized diabetes management is encouraging broader consideration of continuous monitoring technologies among people with type 2 diabetes. Expansion of digital health practices and increasing emphasis on proactive disease management are further supporting adoption within this patient population.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Product	Standalone CGM Devices, Integrated-CGM Insulin Pump Systems	Standalone CGM Devices	Integrated-CGM Insulin Pump Systems
Indication	Type 1 Diabetes, Type 2 Diabetes	Type 1 Diabetes	Type 2 Diabetes
Distribution Channel	Pharmacies, E-commerce, Other	Pharmacies	E-commerce
Connectivity	Bluetooth, 4G/Cellular, Near Field Communication (NFC)	Bluetooth	Near Field Communication (NFC)
Region	North America, Europe, Asia Pacific, Latin America, Middle East & Africa	North America	Asia Pacific

Competitive Landscape and Market Positioning

Key companies in the continuous glucose monitoring devices market:

1. DexCom Inc. (United States)

2. Abbott Laboratories (United States)

3. Medtronic plc (Ireland)

4. F. Hoffmann-La Roche AG (Switzerland)

5. Senseonics Holdings Inc. (United States)

6. Sinocare Inc. (China)

7. i-SENS Inc. (South Korea)

8. Zhejiang POCTech Co. Ltd. (China)

9. Nemaura Medical Inc. (United Kingdom)

10. Bionime Corporation (Taiwan)

Ongoing innovation in diabetes management is accelerating the continuous glucose monitoring devices market, with research focused on improving sensor accuracy, connectivity, and real-time health monitoring. Integration with digital health platforms and wearable technologies continues to enhance patient care and treatment outcomes.

Industry Development/News

Company Name	Date	Key Development
Dexcom	Jun-25	Dexcom unveiled the G8, its next-generation continuous glucose monitoring system. This platform upgrade focuses on advancing sensor performance and expanding the company's product roadmap, signaling a continued commitment to technological innovation and improved long-term glucose management capabilities for diabetes patients.
Zydus Lifesciences	Jun-25	Zydus Lifesciences launched the Diasens and GlucoLive systems, which integrate AI-enabled continuous glucose monitoring into a comprehensive digital care ecosystem. This launch strengthens the company’s competitive positioning in connected diabetes management by combining real-time physiological tracking with digital health tools for both patients and clinical providers.
GlucoModicum	May-25	GlucoModicum unveiled Sofio™, a needle-free glucose monitoring device utilizing magneto-hydrodynamic technology. This innovation represents a significant shift toward non-invasive monitoring, offering a potential alternative to traditional skin-penetrating sensors and aiming to improve patient compliance and reduce the burden of frequent sensor replacement.
Insulet	May-25	Insulet integrated its Omnipod 5 automated insulin delivery system with the Dexcom G7 15-day CGM. This interoperability initiative enhances the functionality of closed-loop diabetes management, enabling seamless communication between insulin delivery hardware and glucose monitoring, which optimizes glycemic control for connected-care users.
Senseonics	May-25	Senseonics partnered with Sequel Med Tech to develop an automated insulin delivery system featuring an extended-duration CGM with up to one-year sensor life. The collaboration accelerates the integration of long-wear sensor technology into advanced insulin management systems, representing a major advancement in operational duration for diabetes monitoring.
Senseonics	Sep-24	Senseonics received FDA approval for the Eversense 365, the industry's first implantable CGM sensor capable of functioning for up to one year. By doubling the longevity of its predecessor and achieving iCGM status, the device provides a long-term monitoring solution that supports seamless integration with automated insulin delivery pumps.
Medtronic	Jul-24	Medtronic received FDA approval for the Simplera CGM, designed to integrate with the company’s Smart Multiple Daily Injection System and InPen. This launch expands the company’s connected ecosystem, facilitating automated data tracking and improving the management of insulin therapy for patients requiring precise, real-time glucose monitoring.
Dexcom	Mar-24	Dexcom received FDA approval for Stelo, an over-the-counter (OTC) continuous glucose monitor designed for Type 2 diabetics not using insulin and wellness-focused users. This launch represents a strategic entry into the consumer health market, providing a prescription-free 15-day sensor option to support proactive health and glycemic management.
Abbott Laboratories	Jan-24	Abbott Laboratories announced that the FreeStyle Libre 2 Plus sensor is now compatible with the Tandem t:slim X2 insulin pump. This integration allows users to utilize Tandem’s Control-IQ hybrid closed-loop technology with Abbott’s 15-day sensor, expanding the clinical utility and interoperability of its glucose monitoring portfolio.
Dexcom	Apr-25	Dexcom received FDA clearance for the Dexcom G7 15-day continuous glucose monitoring system for use by individuals 18 years and older in the U.S. This regulatory milestone extends the sensor wear-time for the G7 platform, improving the cost-efficiency and convenience of the company’s core CGM offering.